Financial Highlights

Genzyme's revenue in 2005 increased 24 percent over 2004, exceeding $2.7 billion. Revenue gains were spread across our diversified business units. Overall, our strategy of diversification has resulted in a 5-year compound annual revenue growth rate of 29 percent.
We capitalized on the interconnections among our strategic acquisitions and our existing businesses, achieving successful integrations while sustaining top- and bottom-line growth. We made acquisitions from late 2004 through 2005 in areas including oncology, cancer diagnostics, orthopaedics, and renal disease.
Reaping the benefit of significant investments made in our pipeline and infrastructure over the past several years, we ended 2005 with a record number of both late-stage and early-stage clinical programs and opened new and expanded manufacturing facilities to support the development and commercialization of these product candidates.